Search Within

Adult Leukemia

Formats
  1. Meeting Abstract (1797)
  2. Journal Article (1605)
  3. Review (122)
  4. Research Letter (55)
  5. Editorial (49)
  6. Book Section (39)
  7. Guidelines (20)
  8. Conference Paper (18)
  9. Correspondence (13)
  10. Miscellaneous (3)
  11. Book Whole (1)
Groups
  1. Center for Hematologic Malignancies (3722)
  2. Department of Medicine (3691)
  3. Hematologic Malignancies, Division of (3687)
  4. GSK Faculty (1783)
  5. Center for Molecular Imaging and Biotechnology (CMIB) (1378)
  6. Executive Committee, Center for Hematologic Malignancies (970)

More Groups

People
  1. Ross Levine (787)
  2. Martin Tallman (655)
  3. David Scheinberg (502)
  4. Jae Park (389)
  5. Eytan Stein (371)
  6. Raajit Rampal (352)

More People

Years
  1. 2025 (105)
  2. 2024 (196)
  3. 2023 (233)
  4. 2022 (255)
  5. 2021 (248)
  6. 2020 (273)

More Years

Publications
  1. Blood (1254)
  2. Journal of Clinical Oncology (217)
  3. Clinical Lymphoma, Myeloma and Leukemia (117)
  4. Leukemia (110)
  5. Haematologica (107)
  6. Cancer Research (86)

More Publications

Publishers
  1. American Society of Hematology (1345)
  2. Nature Publishing Group (325)
  3. Elsevier Inc. (255)
  4. American Association for Cancer Research (234)
  5. American Society of Clinical Oncology (230)
  6. Ferrata Storti Foundation (107)

More Publishers

Results (3722)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • DASFREE: Treatment-free remission (TFR) after discontinuation of dasatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) and deep molecular response (DMR)
    Meeting Abstract

    Shah, N. P.; Garcia-Gutiérrez, V.; Jiménez-Velasco, A.; Larson, S.; Saussele, S.; Rea, D.; Mahon, F. X.; Levy, M. Y.; Gómez-Casares, M. T.; Luciano, L.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2019)

    Fulltext@MSK | Save
  • A multicenter, randomized phase 3 study of asciminib (ABL001) vs bosutinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) previously treated with ≥2 TKIs
    Meeting Abstract

    Mauro, M. J.; Hochhaus, A.; Boquimpani, C.; Minami, Y.; Allepuz, A.; Polydoros, F.; Bédoucha, V.; Aimone, P.; Réa, D.
    Clinical Lymphoma, Myeloma and Leukemia (2019)

    Fulltext@MSK | Save
  • Combination of asciminib, a novel and specific BCR-ABL1 inhibitor, plus imatinib in previously treated chronic myeloid leukemia (CML) patients: Phase 1 study results
    Meeting Abstract

    Talpaz, M.; Cortes, J.; Lang, F.; Kim, D. W.; Réa, D.; Mauro, M. J.; Minami, H.; Breccia, M.; DeAngelo, D. J.; Hochhaus, A.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2019)

    Fulltext@MSK | Save
  • Efficacy and safety of asciminib, a specific allosteric BCR-ABL1 inhibitor targeting the myristoyl-binding site, in patients with chronic myeloid leukemia (CML) carrying the T315I mutation
    Meeting Abstract

    Deininger, M. W.; Réa, D.; Lang, F.; Kim, D. W.; Cortes, J. E.; Hughes, T. P.; Minami, H.; Breccia, M.; DeAngelo, D. J.; Hochhaus, A.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2019)

    Fulltext@MSK | Save
  • Ivosidenib (IVO; AG-120) in IDH1-mutant newly-diagnosed acute myeloid lukemia (ND AML): Updated results from a phase 1 study
    Meeting Abstract

    DiNardo, C. D.; Roboz, G. J.; Stein, E. M.; de Botton, S.; Mims, A. S.; Prince, G. T.; Altman, J. K.; Arellano, M. L.; Donnellan, W.; Erba, H. P.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2019)

    Fulltext@MSK | Save
  • Mutant IDH1 inhibitor ivosidenib (IVO; AG-120) in combination with azacitidine (AZA) for newly diagnosed acute myeloid leukemia (ND AML)
    Meeting Abstract

    DiNardo, C. D.; Stein, A. S.; Stein, E. M.; Fathi, A. T.; Frankfurt, O.; Schuh, A. C.; Döhner, H.; Martinelli, G.; Raffoux, E.; Tan, P.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2019)

    Fulltext@MSK | Save
  • PICALM-MLLT10 fusion commonly presents with extramedullary acute leukemia and often with a mixed phenotype (MPAL)
    Meeting Abstract

    Tashkandi, H.; Xiao, W.; Roshal, M.; Zhang, Y.; Arcila, M.; Benayed, R.; Sen, F.; Ho, C.; Baik, J.; Pichardo, J.; more...
    Modern Pathology (2019)

    Fulltext@MSK | Save
  • Blast to plasmacytoid dendritic cell ratio is predictive of progression in low grade myelodysplastic syndromes
    Meeting Abstract

    Chan, A.; Lewis, N.; Baik, J.; Arcila, M.; Zhang, Y.; Klimek, V.; Roshal, M.; Xiao, W.
    Modern Pathology (2019)

    Fulltext@MSK | Save
  • Emerging translational science discoveries, clonal approaches, and treatment trends in chronic myeloproliferative neoplasms
    Review

    Mughal, T. I.; Pemmaraju, N.; Radich, J. P.; Deininger, M. W.; Kucine, N.; Kiladjian, J. J.; Bose, P.; Gotlib, J.; Valent, P.; Chen, C. C.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • The role of abnormal hemostasis and fibrinolysis in morbidity and mortality of acute promyelocytic leukemia
    Review

    Kwaan, H. C.; Weiss, I.; Tallman, M. S.
    Seminars in Thrombosis and Hemostasis (2019)

    Fulltext@MSK | Save